Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Over the next few years, immuno ...

Then I take a look at the company’s new dividend and buyback strategy, and how that gives me confidence in Regeneron’s long-term cash flow capabilities. In Q4 of 2024, Regeneron reported $1.5B ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

Compared to Q4 2024, Q1 2025 saw a decline in EYLEA net ... pressures and potential delays in key product approvals. Regeneron faced mixed results in Q1 2025 with challenges in its retinal ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price cut by BMO Capital Markets from $865.00 to $800.00 in a research note released on Wednesday morning,Benzinga reports.

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by Guggenheim, and Regeneron Pharmaceuticals maintained their buy rating. The last upgrade for Regeneron ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's ...